Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

This phase 1/2 trial evaluated the maximum tolerated doses, safety, and efficacy of pomalidomide, bortezomib, and dexamethasone (PVD) combination in patients with relapsed lenalidomide-refractory multiple myeloma (MM). In phase 1, dose level 1 consisted of pomalidomide (4 mg by mouth on days 1 to 21...

詳細記述

保存先:
書誌詳細
出版年:Blood
主要な著者: Paludo, Jonas, Mikhael, Joseph R., LaPlant, Betsy R., Halvorson, Alese E., Kumar, Shaji, Gertz, Morie A., Hayman, Suzanne R., Buadi, Francis K., Dispenzieri, Angela, Lust, John A., Kapoor, Prashant, Leung, Nelson, Russell, Stephen J., Dingli, David, Go, Ronald S., Lin, Yi, Gonsalves, Wilson I., Fonseca, Rafael, Bergsagel, P. Leif, Roy, Vivek, Sher, Taimur, Chanan-Khan, Asher A., Ailawadhi, Sikander, Stewart, A. Keith, Reeder, Craig B., Richardson, Paul G., Rajkumar, S. Vincent, Lacy, Martha Q.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2017
主題:
Clinical Trials and Observations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5606008/
https://ncbi.nlm.nih.gov/pubmed/28684537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-782961
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料